Viking Therapeutics is focused on the development of novel therapeutics for patients suffering from metabolic and endocrine disorders.
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of patients recovering from non-elective hip fracture surgery. The Company’s second program is focused on the development of first-in-class, selective, small molecule agonists of the thyroid receptor beta, or TRß, for adrenoleukodystrophy, or ALD, and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis, or NASH. Viking is also developing additional programs targeted at diabetes, metabolic diseases and anemia.
Overview
We have a portfolio of five drug candidates in clinical trials or preclinical studies
Our lead clinical program, VK5211, is a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 is designed to produce the therapeutic benefits of testosterone in muscle and bone with improved safety, tolerability and patient acceptance. We have initiated a Phase 2 clinical trial with VK5211 in patients recovering from non-elective hip fracture surgery. For more information on this study please visit NCT02578095.
Our second pipeline program is focused on the development of novel small molecule agonists of the thyroid beta (TRb) receptor, VK2809 and VK0214. These novel TRb agonists are being developed for hypercholesterolemia and fatty liver disease and X-linked adrenoleukodystrophy, or X-ALD. We have initiated Phase 2 clinical development of VK 2809 in hypercholesterolemia and fatty liver disease. VK0214 is in preclinical development for X-ALD.
We are also developing VK0612, a first-in-class, orally available drug